Howell Moffett

Medpace (United States) — United States

Medicine · Health Sciences

18h-index3.0kcitations34works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(15), Immune Cell Function and Interaction(13), MicroRNA in disease regulation(8), T-cell and B-cell Immunology(5), HIV Research and Treatment(5)

Publications34 total

1085 OPB-101: a mesothelin-specific CAR T cell therapy leveraging protein design to enhance T cell proliferation and persistence for the treatment of ovarian cancer
Regular and Young Investigator Award Abstracts·2024· 1 citedOpen Access
Abstract LB070: In vitro modeling of antigen-driven exhaustion in human CAR T cells
Cancer Research·2024
Abstract 4067: Development of tumor-restricted IL-12 with antigen-dependent expression and localized IL-12 activity
Cancer Research·2024
Abstract 51: OPB-101: An optimized mesothelin-specific CAR T cell product expressing CD8-targeted IL-2/15 and engineered to resist T cell exhaustion
Cancer Research·2024
Outsmart™ IL-2/15, a Novel Cytokine Designed to Enhance ROR1-Specific CAR T Anti-Tumor Activity While Minimizing Treg Activation and Systemic Cytokine Exposure
Blood·2023
Development of a Regulated, Optimized Mesothelin Chimeric Antigen Receptor (CAR) for the Treatment of Mesothelin Positive Cancers
Blood·2023
1047 Protein design and inducible expression allow context-dependent, localized IL-12 activity to enhance solid tumor T cell therapies
Regular and Young Investigator Award Abstracts·2023Open Access
185 Tuning the cell-cell distance via the non-signaling extracellular spacer domain of chimeric antigen receptors is critical for optimal activity
Regular and Young Investigator Award Abstracts·2022Open Access
Safety switch optimization enhances antibody-mediated elimination of CAR T cells
Frontiers in Molecular Medicine·2022· 13 citedOpen Access
Safety switch optimization enhances antibody-mediated elimination of CAR T cells
2022
Abstract 2754: LYL797, a ROR1 CAR T-cell therapy with genetic and epigenetic reprogramming for solid tumors
Cancer Research·2022· 4 cited
B cells engineered to express pathogen-specific antibodies protect against infection
Science Immunology·2019· 146 cited
B cells engineered to express pathogen-specific antibodies using CRISPR/Cas9 protect against infection
2019· 5 citedOpen Access
Abstract IA07: Genetic engineering of therapeutic T cells using synthetic nanoparticles
Cancer Immunology Research·2018
Erratum: The microRNA miR-31 inhibits CD8+ T cell function in chronic viral infection
Nature Immunology·2017· 1 citedOpen Access
Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers
Nature Communications·2017· 170 citedOpen Access
The microRNA miR-31 inhibits CD8+ T cell function in chronic viral infection
Nature Immunology·2017· 69 cited
Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors
Journal of Clinical Investigation·2017· 329 citedOpen Access
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
Nature Nanotechnology·2017· 720 citedOpen Access
Stable inhibitory activity of regulatory T cells requires the transcription factor Helios
Science·2015· 411 cited
page 1 of 2Next →

Frequent Co-authors

Marc J. Lajoie(11), Scott E. Boyken(9), Carl D. Novina(8), Brian D. Weitzner(8), Thaddeus M. Davenport(6), Bradley Hammerson(6), Philip J. Norris(5), Leah Tait(5), Jason K. Yokoyama(5), Aaron E. Foster(5), Matthias T. Stephan(4), Bruce D. Walker(4), Kai W. Wucherpfennig(4), Bijan Boldajipour(4), Lisa Song(4), Kevin G. Haworth(4), Allan Wang(4), Maria M. Steele(4), John T. Crowl(4), Jared Hammer(4)